BioSpace News Archive

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced enrollment of the first patient in the COSIRA-II clinical trial. COSIRA-II (COronary SInus Reducer for the Treatment of Refractory Angina) is a pivotal trial that will study the Neovasc Reducer™ (“Reducer”), designed to reduce angina symptoms in patients with refractory angina.

Strados Labs, a medical technology company harnessing the power of smart sensors, machine learning and proprietary algorithms to provide early detection and predictions of worsening respiratory diseases, announced its pre-series A round of funding at $4.5M.

Each year The National Kidney Foundation considers the work of hundreds of specialists in the field of Nephrology and selects among them those who most exemplify the relentless efforts of NKF to enhance the lives of patients through action, education, and accelerating change.

Boston Children’s Hospital and PM Pediatrics are now working together to provide premier urgent care for children and young adults in the Boston area.

IceCure Medical Ltd., developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, released the following letter to shareholders from its Chief Executive Officer, Eyal Shamir.

Kintara Therapeutics, Inc. announced that its Chief Executive Officer, Robert E. Hoffman will present at the H.C. Wainwright Bioconnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion.

DiaCarta Inc., today announced that the company, under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, will collaborate on the evaluation and development of DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology.

Endotronix, Inc., today announced the U.S. Food and Drug Administration (FDA) has granted approval for an amendment to the company’s PROACTIVE-HF study, a pivotal Investigational Device Exemption (IDE) trial investigating the Cordella Pulmonary Artery (PA) Pressure Sensor.

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA in aggressive cancers, announced that Jennifer Lew has been appointed to its Board of Directors and will serve as chairperson of the Audit Committee.